Abliva’s CEO: We are the leading programme in mitochondrial disease
Abliva is developing drugs for the treatment of mitochondrial diseases, and the company posted positive interim phase II data with its lead candidate KL1333 this summer. Abliva’s CEO Ellen Donnelly stopped by the BioStock Studio to discuss the results and how they impact Abliva’s development moving forward.
Watch the interview with Abliva’s CEO Ellen Donnelly below:
